Skip to content

Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Orthopedic Surgical Operations

Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Orthopedic Surgical Operations

Status
Withdrawn
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03232021
Enrollment
0
Registered
2017-07-27
Start date
2017-08-16
Completion date
2019-04-30
Last updated
2020-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregabalin on Catheter Related Bladder Discomfort

Keywords

urinary bladder, urinary catheters, pregabalin

Brief summary

The aim of this study is to assess the effect of pregabalin administration on catheter-related bladder discomfort (CRBD). The study group includes patients that are about to be subjected to orthopedic operations.

Interventions

DRUGPlacebo oral capsule

Placebo oral capsule administered 1 hour prior to the surgical operation

Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation

Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation

Sponsors

University of Thessaly
CollaboratorOTHER
Saint Savvas Anticancer Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Prospective, double-blind,randomized, placebo controlled trial

Eligibility

Sex/Gender
ALL
Age
45 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* All patients about to be subjected to urinary operations * Signed informed consent

Exclusion criteria

* Preoperative urinary bladder/kidney dysfunction as a result of spinal cord pathology * History of overactive ((urinary frequency\>3 times at night and \>8 times in 24 hours), neurogenic bladder * End stage renal failure * Central nervous system dysfunction * Mental illness/ substance abuse * Sensitivity to pregabalin * Preoperative administration of pregabalin for other indications * Recent bladder catheterization \<3 months

Design outcomes

Primary

MeasureTime frameDescription
Percentage of postsurgical catheter-related bladder discomfort after preoperative pregabalin administrationChange from preoperative status to postoperative one at 0, 1, 2, 6, 24 hours postoperativelyAssessment of discomfort will be made by a scale of four (1=no discomfort, 2=mild discomfort reported on questioning only, 3=moderate discomfort, urge to pass urine reported by the patient without questioning, 4= severe discomfort, urge to pass urine accompanied by behavioral responses, such as flailing limbs, strong vocal responses or attempts to pull the catheter out)

Secondary

MeasureTime frameDescription
Postoperative pain assessed by NPRS scale (Numeric Pain Rating Scale)Total amount of analgesics in morphine analogues administered in the first 24 hours postoperativelyThe goal is to achieve pain scores\<3 as these are assessed by the NPRS scale. In order to achieve that we will record the total amount of milligrams of analogues of morphine administered in the first 24 hours postoperatively
Adverse effects of the drugAll adverse effects observed in the first 24 hours postoperativelyPostoperative nausea and vomiting, confusion, vertigo, blurred vision, dry mouth,sedation, dizziness
Assessment of postoperative sedationIn the operating theatre immediately after patient's extubationThe Ramsay Sedation Scale is used to measure different levels of sedation in medical patients (1=Patient is anxious and agitated or restless, or both 2=Patient is co-operative, oriented, and tranquil, 3=Patient responds to commands only, 4=Patient exhibits brisk response to light glabellar tap or loud auditory stimulus, 5=Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus, 6=Patient exhibits no response)

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026